Organisation paid for research Program year 2023 Source: CMS Open Payments

Cincinnati Rheumatic Disease Study Group

Neither a doctor nor a teaching hospital

Research payments

$250,772

84 payments

Through program year 2023, Cincinnati Rheumatic Disease Study Group is reported as receiving $250,772 in research payments, across 84 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $385 1
2022 Research $450 9
2021 Research $5,600 14
2020 Research $52,010 28
2019 Research $192,327 32

Breakdown

Who paid Research payments · program years 2019–2023
  1. Novartis Pharmaceuticals Corporation $137,581 2 payments
  2. Pfizer Inc. $58,189 29 payments
  3. Sun Pharmaceutical Industries Inc. $49,617 50 payments
  4. Ucb SA $5,385 3 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Randomized, Double-Blind, Parallel-Group, Multicenter Study of Secukinumab to Compare 300 MG and 150 MG at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During An Initial 16 We $137,581 2 payments
  2. Phase 3B4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor TNF Inhibitor in Subjects With Rheumatoid Arthritis $55,024 25 payments
  3. A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis. $30,383 13 payments
  4. A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab $11,297 8 payments
  5. A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis $6,741 4 payments
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $5,385 3 payments
  7. A Longterm Openlabel Extension Study of Tofacitinib Cp690550 for the Treatment of Psoriatic Arthritis $3,165 4 payments
  8. Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $600 12 payments
  9. Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $450 9 payments
  10. A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $146 4 payments
What the money was spent on Research payments · program years 2019–2023
  1. Other $48,567 29 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record